Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan
Observational study shows finerenone reduces proteinuria in diabetic nephropathy patients on RAAS and SGLT2 therapy, suggesting new management strategies.
Key Points
Finerenone reduced proteinuria by an average of 7.3% in a cohort of 33 diabetic nephropathy patients.
66.7% of patients responded to finerenone treatment, indicating effective proteinuria management.
Baseline albuminuria levels influenced treatment response, with higher reductions in moderate to severe cases.
The treatment was well tolerated, with mild hyperkalemia in 15.2% of participants, but renal function remained stable.